Published November 23, 2015, Phase II trial results. Patients enrolled from June 2013 to April 2014. 122 evaluable patients who were all resistant to Crizotinib; overall objective response rate (ORR) of 50%. Disease Control Rate (DCR) was 79%. Median duration of response was 11.2 months.
Of 96 patients previously treated with chemotherapy the ORR was 45%.
Median progression free survival (PFS) for all patients was 8.9 months.
Central nervous system (CNS) DCR was 83%, ORR of 57%.
Alectinib remained effective longer in the brain than the body.